TORONTO, May 13, 2024 /PRNewswire/ -- MolecuLight
Inc., the global leader in fluorescence imaging technology for
real-time detection of harmful bacteria in wound care, is proud to
announce that a groundbreaking study led by Dr. Rosemarie Derwin and colleagues, titled
"Integrating Point-of-Care Bacterial Fluorescence Imaging-Guided
Care with Continued Wound Measurement for Enhanced Wound Area
Reduction Monitoring," has been awarded Best Abstract of the
Year at the prestigious European Wound Management Association
(EWMA) conference held in London,
UK this May 2024.
This year's EWMA meeting received an impressive influx of almost
5000 participants, and over 1000 abstract submissions were received
from 68 countries spanning 6 continents. Being honored with the
Best Abstract of the Year award is a significant
acknowledgment of MolecuLight's substantial contribution to the
field of wound care and underscores its growing recognition among
esteemed thought leaders in the industry.
The study upon which this abstract is founded was published
earlier this year in the high-impact Diagnostics journal. Its
findings underscore the undeniable correlation between the presence
of fluorescence signals, detected by MolecuLight imaging devices,
and poorer wound healing outcomes evidenced by poor wound area
reduction. The study authors also yielded insightful revelations by
comparing their manual measurement technique against digital
measurement using the MolecuLight device. Manual (ruler) techniques
overestimated wound size by approximately 23%, where measurement
consistency over time heavily relied on the operator. Consistency
could only be maintained when all measurements were conducted by
the same individual, employing the same methodology, and under
identical conditions – however this scenario seldom reflects
real-world practices. This emphasizes the value proposition of
MolecuLight's highly accurate, consistent, and repeatable digital
wound measurement technology1.
Dr. Rosemarie Derwin, lead author
of the study remarks, "Our comparison of manual and digital
measurement techniques revealed that discrepancies in measurement
are a real issue when the same operator isn't involved in the care
of a patient throughout. Ideally, all wound care providers would
have access to digital measurement tools. MolecuLight provides this
capability alongside the critically important visualization of
bacteria in wounds at the bedside, a transformative innovation in
wound diagnostics." She continues, "We are thrilled to receive this
recognition from EWMA, which signifies a resonance of our work with
global thought leaders in the field of wound care."
"At MolecuLight, we're committed to providing healthcare
providers with empowering tools for proactive intervention and
enhanced patient care," says Anil Amlani, CEO at MolecuLight Inc.,
"This award underscores the effectiveness of our platform in
revolutionizing global wound management by addressing the
challenges posed by unstandardized practices in wound care. We
believe that objective bacterial detection and precise digital
wound measurement should be the standard at every bedside, enabling
clinicians to act decisively, supporting documentation of medical
necessity for payers, and aligning with optimal product usage
recommendations from skin therapeutic manufacturers."
1 Raizman, R. et al. J Wound Care, 2019,
DOI:10.12968/jowc.2019.28.12.824.
About MolecuLight Inc.
MolecuLight Inc. is a
privately owned medical imaging company with global presence that
offers fully commercialized point-of-care digital wound measurement
and real-time bacterial detection through fluorescence imaging
platform technology.
MolecuLight's suite of commercial devices,
which include the MolecuLight i:X® and
DX™ fluorescence imaging and digital wounds measurement
systems and their accessories, have scientifically proven
capabilities that enhance wound care practices and outcomes across
all places of service. MolecuLight procedures performed in
the United States benefit from an
available reimbursement pathway which includes two CPT®
codes for physician work to perform "fluorescence
imaging for bacterial presence
location, and load" and facility
payment for Hospital
Outpatient Department (HOPD) and Ambulatory Surgical
Center (ASC) settings through an Ambulatory Payment Classification
(APC) assignment.
For sales, media or other inquiries or further information,
please contact
Carolina
Wuesthoff, MD
Global Manager, Medical Engagement & Communications
MolecuLight Inc.
cwuesthoff@moleculight.com
T. +1.647.362.4684
www.moleculight.com
Photo -
https://mma.prnewswire.com/media/2410462/MolecuLight_MolecuLight_s_Innovative_Approach_Awarded_Best_Abstr.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/moleculights-innovative-approach-awarded-best-abstract-at-ewma-2024-302143043.html